What is the 13F Pro Quality Score for FDMT?

13F Pro ranks 4D Molecular Therapeutics, Inc. (FDMT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FDMT's current score at https://13fpro.ai/research/FDMT (free sign-up required for the full ranking).

Where does 13F Pro source FDMT data?

All 4D Molecular Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. 4D Molecular Therapeutics, Inc. files with the SEC under CIK 1650648. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FDMT in?

4D Molecular Therapeutics, Inc. (FDMT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FDMT research updated on 13F Pro?

FDMT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

4D Molecular Therapeutics, Inc.(FDMT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1650648 FDMT stock profile & AI dashboard →

13F Pro Quality Score

23.2/100

Rank #2,620 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.1/100

Profitability

0.8/100

Balance Sheet

4.8/100

Earnings Quality

30.0/100

Free Cash Flow

0.6/100

Institutional Flow

6.7/100

Revenue Scale

1.4/100

Dilution Risk

7.3/100

FDMT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for 4D Molecular Therapeutics, Inc. (FDMT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FDMT at 23.2/100 on a 32-signal composite quality model, placing it at rank #2,620 of 2,879 stocks — the bottom half of the AI-ranked universe. FDMT scores in the top quartile across revenue growth (99.1). Areas of concern include free cash flow (0.6) and profitability (0.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), 4D Molecular Therapeutics, Inc. reports quarterly revenue of $3.0M, net income of $-68.8M, free cash flow of $-68.1M. Top institutional holders of FDMT by reported 13-F value include JANUS HENDERSON GROUP PLC, RA CAPITAL MANAGEMENT, L.P., GOLDMAN SACHS GROUP, based on the most recent SEC filings. FDMT trades on the Nasdaq exchange and files with the SEC under CIK 1650648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FDMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 4D Molecular Therapeutics, Inc. directly from SEC EDGAR. 4D Molecular Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 42 since 2021, currently 23.2 — a stable long-term trajectory across 55 quarterly and live scoring snapshots.

✦

Fun facts about 4D Molecular Therapeutics, Inc.

Quirks, history, and lore behind FDMT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biotechnology company · listed on Nasdaq · headquartered in California · focused on gene therapy.
2
The Numbers
A pre-revenue biotech with a market cap in the hundreds of millions — the pipeline is the entire value proposition, not any product on a pharmacy shelf yet.
3
The History
Founded in the 2010s, it was built around a proprietary library of adeno-associated virus (AAV) capsids engineered to reach tissues that older gene therapy vectors couldn't reliably hit.
4
The Secret
Its whole edge lives in a capsid engineering platform — essentially a lock-picking kit for getting therapeutic genes past the body's defenses and into exactly the right cells.
5
The Lore
Its ticker starts with the letter F despite the company's name starting with a 4 — because stock exchanges have opinions about numerals leading a symbol.
6
The Giveaway
The name literally puts four dimensions in the brand — a nod to the four protein subunits of an AAV capsid — and the pipeline targets diseases of the eye, lung, liver, and heart.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.0M

Net Income

Q1 2026

$-68.8M

Free Cash Flow

Q1 2026

$-68.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+230194.6% YoY

$85.2MFY 2025

FY22 $3.1MFY23 $20.7MFY24 $37.0KFY25 $85.2M

Net Income

+12.9% YoY

$-140.1MFY 2025

FY22 $-107.5MFY23 $-100.8MFY24 $-160.9MFY25 $-140.1M

Operating Income

+15.1% YoY

$-159.5MFY 2025

FY22 $-110.0MFY23 $-112.9MFY24 $-187.8MFY25 $-159.5M

EPS (Diluted)

+18.8% YoY

$-2.42FY 2025

FY22 $-3.32FY23 $-2.58FY24 $-2.98FY25 $-2.42

Total Assets

+1.1% YoY

$566.7MFY 2025

FY22 $261.8MFY23 $339.9MFY24 $560.4MFY25 $566.7M

Op. Cash Flow

+18.9% YoY

$-109.1MFY 2025

FY22 $-86.7MFY23 $-75.8MFY24 $-134.6MFY25 $-109.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$85.2M +230194.6%	$37.0K -99.8%	$20.7M +562.3%	$3.1M -82.7%	$18.0M +32.5%	$13.6M
Net Income	$-140.1M +12.9%	$-160.9M -59.5%	$-100.8M +6.2%	$-107.5M -50.7%	$-71.3M -25.8%	$-56.7M
Operating Income	$-159.5M +15.1%	$-187.8M -66.4%	$-112.9M -2.6%	$-110.0M -54.3%	$-71.3M -25.9%	$-56.7M
EPS (Diluted)	$-2.42 +18.8%	$-2.98 -15.5%	$-2.58 +22.3%	$-3.32 -29.2%	$-2.57	—
Total Assets	$566.7M +1.1%	$560.4M +64.9%	$339.9M +29.8%	$261.8M -25.9%	$353.5M +22.6%	$288.3M
Operating Cash Flow	$-109.1M +18.9%	$-134.6M -77.6%	$-75.8M +12.6%	$-86.7M -25.4%	$-69.1M -35.8%	$-50.9M

Get alerted when FDMT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for 4D Molecular Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FDMT

JANUS HENDERSON GROUP PLC
$48.9M5,247,151 sh
RA CAPITAL MANAGEMENT, L.P.
$47.0M5,049,779 sh
GOLDMAN SACHS GROUP INC
$39.2M4,205,438 sh
BlackRock, Inc.
$38.6M4,145,303 sh
Novo Holdings A/S
$34.0M3,650,737 sh
BVF INC/IL
$26.8M2,879,289 sh
STATE STREET CORP
$25.2M2,707,875 sh
ARMISTICE CAPITAL, LLC
$18.6M2,000,000 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$14.9M1,605,156 sh
FEDERATED HERMES, INC.
$13.3M1,432,260 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$48.9M	5,247,151
RA CAPITAL MANAGEMENT, L.P.	$47.0M	5,049,779
GOLDMAN SACHS GROUP INC	$39.2M	4,205,438
BlackRock, Inc.	$38.6M	4,145,303
Novo Holdings A/S	$34.0M	3,650,737
BVF INC/IL	$26.8M	2,879,289
STATE STREET CORP	$25.2M	2,707,875
ARMISTICE CAPITAL, LLC	$18.6M	2,000,000
ADAGE CAPITAL PARTNERS GP, L.L.C.	$14.9M	1,605,156
FEDERATED HERMES, INC.	$13.3M	1,432,260

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FDMT on your watchlist

Track score changes the day 4D Molecular Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FDMT a good stock to buy?

13F Pro's AI-powered analysis of 4D Molecular Therapeutics, Inc. (FDMT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FDMT are available on the FDMT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FDMT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FDMT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of 4D Molecular Therapeutics, Inc.'s investment landscape.